Hospira, Inc. (NYSE: HSP), a global specialty pharmaceutical and medication delivery company, today launched a new online U.S. product catalog, available at Hospira.com/catalog. Developed with input from customers, the new website allows healthcare facilities and other medical care providers to search Hospira's more than 1,200 products in a variety of ways – alphabetically, by product name, list number, or therapeutic class.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/hospira/48828/
Cancun spring break can prove to be great one for couples and families seeking some quality time together. For some Cancun has also proved to be a therapeutic center as it provides some excellent treatment for people recovering from ailments.
Abbott announced today that the U.S. Food and Drug Administration has approved the company’s Absorb bioresorbable heart stent, making the first-of-its-kind medical device commercially available to treat people with coronary artery disease in the United States.
Absorb is the only fully dissolving stent approved for the treatment of coronary artery disease, which affects 15 million people in the United States and remains a leading cause of death worldwide, despite decades of therapeutic advances. While stents are traditionally made of metal, Abbott’s Absorb stent is made of a naturally dissolving material, similar to dissolving sutures. Absorb disappears completely in approximately three years, after it has done its job of keeping a clogged artery open and promoting healing of the treated artery segment. By contrast, metal stents are permanent implants that restrict vessel motion for the life of the person treated.
To view the multimedia release go to:
http://www.multivu.com/players/English/7826651-abbott-fda-approval-stent/
Federally funded research that provides a deep understanding of cancer is spurring advances against many types of the disease. With a strong bipartisan commitment from Congress to keep investment in biomedical research a national priority, we can accelerate our pace of progress and save more lives from cancer, according to the seventh annual American Association for Cancer Research (AACR) Cancer Progress Report, released today.
Basic research in the fields of immunology and cancer genetics has recently been harnessed to develop two new forms of cancer treatment: immunotherapy and precision medicine. As detailed in the report, the utility of these treatments is expanding rapidly. In May 2017, the U.S. Food and Drug Administration (FDA) heralded a new dawn for precision medicine when it approved the immunotherapeutic pembrolizumab (Keytruda) for treating patients with any solid tumor harboring specific genetic characteristics. This is the first anticancer therapeutic approved based on cancer biomarkers rather than the location in the body where the cancer originated.
To view the multimedia release go to:
https://www.multivu.com/players/English/8155051-aacr-cancer-progress-report-2017/
Ethicon* joins world-renowned experts in bariatric surgery to share the latest breakthroughs in science and innovation that are advancing surgery in the fight against obesity and metabolic diseases during ObesityWeek 2016, the combined annual meeting of the American Society for Metabolic & Bariatric Surgery (ASMBS) and The Obesity Society (TOS). Ethicon will highlight the growing body of research and evidence on the benefits of bariatric surgery, a new sleeve gastrectomy training module on the Touch Surgery app, and its comprehensive portfolio of bariatric surgery products aimed to improve patient outcomes.
“Ethicon’s mission is to lead the way in resolving the burden of obesity for both patients and healthcare systems by expanding access to care and demonstrating the critical value of treatment through research and evidence, while also enabling new technologies,” said Dr. Elliott Fegelman, Therapeutic Area Expert, Metabolics, Johnson & Johnson Innovation.
To view the multimedia release go to:
http://www.multivu.com/players/English/7965651-ethicon-bariatric-surgery-access-obesity-week-2016/
Countless women have said “Thank You Curél®” for relieving their dry skin. Now the Curél® Skincare team is giving people a whole new reason to say “Thanks”. This Thanksgiving, the experts behind Curél® Skincare are joining forces with lifestyle expert Katie Brown and Meals On Wheels Association of America to help care for friends, family, and those in need. From teaming up with Katie, to sharing smart holiday survival tips, Curél® Skincare is going beyond providing therapeutic skincare to supporting Meals On Wheels’ mission, which is to ensure that everyone has the comfort and care they deserve during the holidays. At a time when we all think about what we have to be thankful for, Curél® Skincare is giving everyone a reason to be thankful.
To view Multimedia News Release, go to http://www.multivu.com/mnr/53289-katie-brown-teams-up-with-curel-skincare-support-meals-on-wheels
